QuidelOrtho Corporation (QDEL) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals several concerning factors: negative cash flows, increased inventory levels, and a significant decline in respiratory revenue impacting overall margins. Additionally, the guidance for Q2 is flat, with uncertainties in China affecting revenue. Despite some positive developments in product launches and long-term margin improvements, the immediate outlook remains challenged. Given the company's small-cap status, these negative aspects are likely to result in a stock price decline over the next two weeks.
Key Financial Performance
Total Reported Revenue $620 million, with non-respiratory revenue at $552 million ($544 million excluding Donor Screening business). Labs revenue declined 8% year-over-year due to a softer respiratory season, termination of a joint business agreement with Grifols, and macroeconomic/geopolitical headwinds.
Immunohematology Revenue Grew 3% year-over-year, driven by North America, China, and JPAC.
Respiratory Revenue $68 million, significantly down year-over-year due to approximately 30% lower influenza-like illness (ILI) visits compared to Q1 2025, reflecting a milder and shorter respiratory season.
Adjusted Gross Profit Margin 44%, a decrease of 630 basis points year-over-year due to product mix with lower respiratory revenue contribution.
Adjusted EBITDA $109 million, representing an 18% adjusted EBITDA margin. Year-over-year decline attributed to lower respiratory revenue and macroeconomic/geopolitical pressures.
Operating Cash Flow Negative $33 million, with free cash flow at negative $67 million. Year-over-year decline due to lower EBITDA, timing of accounts payable, accrued interest, and increased inventory from weaker respiratory season and preparation for product launches.
Accounts Receivable Cash Collections $54 million, showing strong performance.
Capital Expenditures (CapEx) Reduced by $22 million year-over-year due to lower systems and manufacturing capacity spend.
Net Debt to Adjusted EBITDA Leverage 4.1x, with expectations to reduce to 3.25-3.5x by the end of 2026.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
LEX Diagnostics Acquisition: Acquired LEX Diagnostics, adding an ultra-fast molecular platform to strengthen point-of-care diagnostics. Manufacturing capacity is being expanded in the U.K. with instrument placements expected this quarter and revenue starting in early 2027.
High-Sensitivity Troponin Assay: Launched in the U.S., strengthening the cardiac portfolio. Currently shipping to over 300 U.S. customers.
VITROS 450 Platform: Rolled out in select international markets as a successor to the VITROS 350, targeting emerging markets with low-volume, cost-effective solutions. Initial shipments targeted for JPAC, followed by LATAM and EMEA.
China Market Impact: Sales slowed in March due to anticipated national IVD pricing guidelines. Pricing changes expected to impact half of sales in China starting mid-2027, but the business is expected to remain accretive to margins.
Middle East Disruption: Delays in orders and tenders due to ongoing disruptions, with expectations for resumption later in the year.
Adjusted EBITDA Margin Expansion: Focused on expanding adjusted EBITDA margin through staffing reductions, procurement, and facility consolidation cost savings.
Cash Flow Improvement: Targeting positive cash flow of $100 million to $120 million for 2026, driven by higher revenue in the second half of the year.
Molecular Diagnostics Investment: Continued investment in molecular diagnostics as a strategic growth area, including the ramp-up of the LEX Diagnostics business.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Softer respiratory season: The first quarter results were impacted by a significantly milder and shorter respiratory season compared to Q1 2025, with influenza-like illness (ILI) visits down approximately 30%. This led to lower respiratory revenue and affected overall financial performance.
Macroeconomic and geopolitical headwinds: Broader macroeconomic and geopolitical challenges, including disruptions in the Middle East, caused delays in orders and tenders, impacting revenue.
China National IVD pricing guidelines: Sales in China slowed due to anticipated national IVD pricing guidelines, with distributors exercising caution on inventory purchases. The proposed pricing changes are expected to impact about half of the company's sales in China starting mid-2027.
Termination of joint business agreement with Grifols: The termination of the joint business agreement with Grifols reduced Q1 Labs revenue and created a difficult year-over-year comparison.
Weaker cash flow in Q1 2026: Operating cash flow was negative $33 million, and free cash flow was negative $67 million, primarily due to lower EBITDA from the weaker respiratory season and timing of accounts payable and accrued interest.
Inventory buildup: Inventory levels increased due to the weaker respiratory season and preparation for upcoming product launches, which could strain cash flow and operational efficiency.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
China National IVD Pricing Guidelines Impact: The company anticipates the implementation of China's national IVD pricing guidelines to impact approximately half of its sales in China starting mid-2027. Despite this, the China business is expected to remain accretive to the company's margin profile.
Order and Tender Delays in the Middle East: Assuming stabilization of conditions, the company expects delayed orders and tenders in the Middle East to resume during the remainder of 2026.
Adjusted EBITDA Margin Expansion: The company aims to expand its adjusted EBITDA margin and improve cash flow in 2026 through targeted staffing reductions, procurement, and facility consolidation cost savings initiatives.
LEX Diagnostics Launch: The company plans to begin placing LEX Diagnostics instruments in Q2 2026, with measurable assay pull-through and associated revenue expected in early 2027.
VITROS 450 Platform Rollout: The company is rolling out the VITROS 450 platform in select international markets, targeting JPAC, LATAM, and EMEA regions. This is expected to support mid-single-digit revenue growth for the labs business.
Full Year 2026 Revenue Guidance: The company has updated its full-year 2026 revenue guidance to $2.7 billion to $2.75 billion, reflecting lower revenue expectations in China and a weaker respiratory season in North America.
Respiratory Revenue Forecast: The company forecasts an 8% decline in respiratory revenue for the full year 2026, assuming an average respiratory season without a rebound in the second half.
Adjusted EBITDA and EPS Guidance: The company expects full-year 2026 adjusted EBITDA of $615 million to $630 million, representing a 23% adjusted EBITDA margin, and adjusted diluted EPS of $1.80 to $2.00.
Free Cash Flow Guidance: The company expects to generate positive free cash flow of $100 million to $120 million for the full year 2026, driven by higher revenue in the second half.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Could you walk us through the guide for second quarter growth by segment and what margins are expected to look like?
A:Sequentially, Q2 is expected to be relatively flat with Q1 but will show year-over-year growth. Growth will come from the core business, including labs, IH, and Triage.
Q:Can you provide details on the China NHSA headwind in 2026 and how it was factored into the guidance?
A:The updated revenue guide is tethered to the low end of the previous guide, with a $75 million reduction at the midpoint. This is split roughly 45% due to respiratory season weakness and 30% due to China distributor pauses related to pending national pricing guidelines.
Q:If Q2 is sequentially flat to Q1, what factors will drive the significant ramp in adjusted EBITDA margin in Q3 and Q4?
A:Revenue growth is expected to pick up in the second half due to reduced China impacts, continued growth in labs, IH, and Triage, and an average respiratory season. New products like VITROS 450 and high-sensitivity troponin will also contribute.
Q:What are the switching costs for customers adopting the LEX platform, and how are you addressing them?
A:Switching costs are minimal as most instruments will be placed in customers without capital outlay. The LEX platform is plug-and-play, offering ease of use, speed, and cost advantages. The company is also building additional capacity to meet demand.
Q:What is your commitment to the China market given recent competitor exits and reimbursement changes?
A:The company remains committed to China despite reimbursement changes, which will impact about half of sales. The business is still accretive to margins, and actions are being taken to offset changes. Long-term, China remains an attractive growth market.
Q:What actions are being taken to improve margins, both this year and in the future?
A:The company has reduced 1,000 positions, exited Donor Screening, and is optimizing procurement and site consolidation. LEX and molecular margins are expected to drive mid-to-high 20s% EBITDA margins by mid-2027.
Q:Can you provide more color on the China impact in the first half and whether distributor behavior is stabilizing?
A:Distributors were cautious due to reimbursement changes, but the company is offering rebates and discounts to stabilize behavior. This is expected to improve over the next two months.
Q:Are you still confident in achieving mid-to-high 20s% EBITDA margins by mid-2027 despite potential changes in China?
A:Yes, the company remains confident in its margin goals and timeline due to ongoing procurement and site consolidation initiatives. Cost mitigation actions are planned to offset potential price declines in China.
Q:Review of Unclear Management Responses
A:None of the questions were avoided or lacked clarity. Management provided detailed and direct responses to all questions.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CDC visit
CE combination
China guideline
China margin
China sale
Customer insight
Diagnostics platform
ECiQ solution
EMEA CE
East condition
IVD pricing
LEX
President Investor
VITROS platform
Vice President
afternoon today
care
expectation
headwind
illness
information investor
investor relation
lab
launch
order tender
page website
pricing change
pricing guideline
priority
relation page
season
QDEL Transcript
QuidelOrtho Corporation (QDEL) Q1 2026 Earnings Call Transcript
Unknown5-6
The earnings call reveals several concerning factors: negative cash flows, increased inventory levels, and a significant decline in respiratory revenue impacting overall margins. Additionally, the guidance for Q2 is flat, with uncertainties in China affecting revenue. Despite some positive developments in product launches and long-term margin improvements, the immediate outlook remains challenged. Given the company's small-cap status, these negative aspects are likely to result in a stock price decline over the next two weeks.
QuidelOrtho Corporation (QDEL) Q4 2025 Earnings Call Transcript
Unknown2-11
The earnings call provides mixed signals: while revenue and EBITDA guidance are positive, free cash flow fell short due to timing issues. The Q&A reveals sustainable growth in the Lab segment and strategic partnerships, but also highlights uncertainties in respiratory revenue and flat gross margins. The market cap indicates a moderate reaction, leading to a neutral prediction for stock price movement.
QuidelOrtho Corporation (QDEL) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Neutral12-3
Curaleaf Holdings, Inc. (CURA:CA) Q3 2025 Earnings Call Transcript
Unknown11-6
The earnings call presents mixed signals. Positive aspects include international growth, improved gross margins, and cash flow generation. However, declines in retail revenue, net loss, and unclear management responses on future margin expansion and regulatory impacts are concerns. The market cap suggests moderate volatility, leading to a neutral stock price prediction.
QDEL Slides
QDEL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
